J&J revenue misses on lower-than-expected pharmaceutical sales
[BENGALURU] Johnson & Johnson, which is in the process of completing its US$30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts' estimates, hurt by lower demand for its pharmaceutical products.
The diversified healthcare company's sales rose to US$17.77 billion in the first quarter from US$17.48 billion a year earlier, but came in below analysts' average estimate of US$18.04 billion, according to Thomson Reuters I/B/E/S.
Pharmaceutical sales rose 0.8 per cent to US$8.25 billion, below Barclays estimate of US$8.47 billion.
Net earnings in the quarter were US$4.42 billion, or US$1.61 per share, compared with US$4.46 billion, or US$1.59 per share, in the year-earlier period.
Excluding items, the company earned US$1.83 per share, beating Street expectations of US$1.77 per share.
J&J is the first among major pharmaceutical companies to report quarterly results, a month after the Republican attempt to overhaul the US healthcare system spectacularly failed, although a renewed effort is said to be in the works.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself
Japan’s Uniqlo opens Rome store as part of European expansion